Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Bert Vogelstein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0766-3854; OpenAlex author ID A5072858943; NIH RePORTER profile ID 1863957. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
2
Labs led
0
Collaborators
89
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: none · 2022: 1 grant · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 16

  1. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1. Co-author DOI 10.7554/elife.94488↗
  2. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Co-author DOI 10.7554/elife.94488.3↗
  3. Radiologists' Expectations of Artificial Intelligence in Pancreatic Cancer Imaging: How Good Is Good Enough? Co-author DOI 10.1097/rct.0000000000001503↗
  4. Deep lessons learned: Radiology, oncology, pathology, and computer science experts unite around artificial intelligence to strive for earlier pancreatic cancer… Co-author DOI 10.1016/j.diii.2019.09.002↗
  5. Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features. Co-author DOI 10.1016/j.diii.2020.03.002↗
  6. Application of Deep Learning to Pancreatic Cancer Detection: Lessons Learned From Our Initial Experience. Co-author DOI 10.1016/j.jacr.2019.05.034↗
  7. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  8. Utility of CT Radiomics Features in Differentiation of Pancreatic Ductal Adenocarcinoma From Normal Pancreatic Tissue. Co-author DOI 10.2214/ajr.18.20901↗
  9. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Co-author DOI 10.1038/ng.3764↗
  10. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  11. Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Co-author DOI 10.1007/s10689-014-9755-y↗
  12. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Co-author DOI 10.1158/1078-0432.ccr-14-2600↗
  13. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Co-author DOI 10.1158/0008-5472.can-14-0734↗
  14. Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-1271↗
  15. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Co-author DOI 10.1158/1078-0432.ccr-12-0827↗
  16. ATM mutations in patients with hereditary pancreatic cancer. Co-author DOI 10.1158/2159-8290.cd-11-0194↗

Grants 2

  1. Core 2: Biospecimen/Pathology Core P50CA062924↗
  2. Lustgarten Laboratory at Johns Hopkins (early detection and genetics) AWARD lustgarten:na-bert-vogelstein-lustgarten-laboratory-at-johns-hopkins-e

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenneth W. Kinzler · 15 shared papers, 1 shared grant, 2012–2025 · strength 1.57
  2. Ralph H. Hruban · 11 shared papers, 1 shared grant, 2012–2023 · strength 0.97
  3. Nickolas Papadopoulos · 9 shared papers, 2012–2025 · strength 0.72
  4. Elliot K. Fishman · 6 shared papers, 2014–2023 · strength 0.59
  5. Linda Chi Hang Chu · 5 shared papers, 2019–2023 · strength 0.56
  6. Surojit Sur · 4 shared papers, 2012–2025 · strength 0.47
  7. Marco Dal Molin · 3 shared papers, 2015–2025 · strength 0.45
  8. Satomi Kawamoto · 4 shared papers, 2019–2023 · strength 0.43
  9. Alison P. Klein · 4 shared papers, 1 shared grant, 2012–2022 · strength 0.42
  10. Jordina Rincón-Torroella · 2 shared papers, 2025 · strength 0.41
  11. Nilofer Saba Azad · 2 shared papers, 2025 · strength 0.41
  12. Anne Marie Lennon · 2 shared papers, 1 shared grant, 2014–2022 · strength 0.38
  13. Alan Yuille · 4 shared papers, 2019–2020 · strength 0.38
  14. Michael Goggins · 3 shared papers, 1 shared grant, 2012–2022 · strength 0.37
  15. Anirban Maitra · 2 shared papers, 1 shared grant, 2012–2022 · strength 0.35
  16. Edmund M. Weisberg · 2 shared papers, 2020–2023 · strength 0.30
  17. Francis M Giardiello · 1 shared grant, 2022 · strength 0.27
  18. Robert A. Anders · 1 shared grant, 2022 · strength 0.27
  19. Elizabeth Thompson · 1 shared grant, 2022 · strength 0.27
  20. Francis Giardiello · 1 shared grant, 2022 · strength 0.27
  21. Elizabeth M. Jaffee · 1 shared grant, 2022 · strength 0.27
  22. Scott E Kern · 1 shared grant, 2022 · strength 0.27
  23. Ammar A. Javed · 2 shared papers, 2019–2023 · strength 0.25
  24. Christopher Lee Wolfgang · 4 shared papers, 2014–2019 · strength 0.18
  25. Taha Muneer Ahmed · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.